Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting

The advent of molecular diagnostics and the rising number of targeted therapies have facilitated development of precision oncology for cancer patients. In order to demonstrate its impact for patients with metastatic breast cancer (mBC), we initiated a Molecular Tumor Board (MTB) to provide treatment recommendations for mBC patients who had disease progression under standard treatment. NGS (next generation sequencing) was carried out using the Oncomine multi-gene panel testing system (Ion Torrent). The MTB reviewed molecular diagnostics’ results, relevant tumor characteristics, patient’s course of disease and made personalized treatment and/or diagnostic recommendations for each patient. From May 2017 to December 2019, 100 mBC patients were discussed by the local MTB. A total 72% of the mBC tumors had at least one molecular alteration (median 2 per case, range: 1 to 6). The most frequent genetic changes were found in the following genes: PIK3CA (19%) and TP53 (17%). The MTB rated 53% of these alterations as actionable and treatment recommendations were made accordingly for 49 (49%) patients. Sixteen patients (16%) underwent the suggested therapy. Nine out of sixteen patients (56%; 9% of all) experienced a clinical benefit with a progression-free survival ratio ≥ 1.3. Personalized targeted therapy recommendations resulting from MTB case discussions could provide substantial benefits for patients with mBC and should be implemented for all suitable patients.

[1]  T. Fehm,et al.  Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet , 2020, Breast Care.

[2]  K. Metzeler,et al.  NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU , 2020, Archives of Gynecology and Obstetrics.

[3]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[4]  S. Fox,et al.  Clinical implications of prospective genomic profiling of metastatic breast cancer patients , 2020, Breast Cancer Research.

[5]  Mark Robson,et al.  Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Ebner,et al.  Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients , 2020, Scientific Reports.

[7]  H. Kölbl,et al.  Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real‐World Precision Cancer Medicine Platform , 2020, The oncologist.

[8]  Jeremy L. Warner,et al.  A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants , 2020, Frontiers in Cell and Developmental Biology.

[9]  Aung Ko Win,et al.  Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis , 2019, International journal of cancer.

[10]  S. Fröhling,et al.  Community-driven development of a modified progression-free survival ratio for precision oncology , 2019, ESMO Open.

[11]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[12]  A. Iafrate,et al.  FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer , 2019, Clinical Cancer Research.

[13]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[14]  S. Piha-Paul,et al.  Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Sicklick,et al.  Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.

[16]  J Jack Lee,et al.  Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.

[17]  C. Sotiriou,et al.  Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Melanie Boerries,et al.  Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience , 2018, JCO precision oncology.

[19]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  J. Hainsworth,et al.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[22]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[23]  S. Sleijfer,et al.  Molecular Tumor Boards: current practice and future needs , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  B. Taylor,et al.  Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. , 2017, Cold Spring Harbor perspectives in medicine.

[25]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[26]  S. Narod,et al.  The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients , 2017, Breast Cancer Research and Treatment.

[27]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[28]  T. de Baère,et al.  The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial , 2016, Genetics in Medicine.

[29]  A. Garg,et al.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Myers,et al.  Advancements in Next-Generation Sequencing. , 2016, Annual review of genomics and human genetics.

[31]  Howard Kaufman,et al.  Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers , 2016, The oncologist.

[32]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[33]  Christine Y. Lu,et al.  Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study , 2016, BMJ Open.

[34]  S. Baum,et al.  Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors. , 2016, Anticancer research.

[35]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[36]  J. Neal,et al.  Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. , 2015, Translational lung cancer research.

[37]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[38]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[39]  J Jack Lee,et al.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Razelle Kurzrock,et al.  Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. , 2015, Journal of oncology practice.

[41]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[42]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[43]  S. Lippman,et al.  Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.

[44]  N. Iqbal,et al.  Imatinib: A Breakthrough of Targeted Therapy in Cancer , 2014, Chemotherapy research and practice.

[45]  S. Mai,et al.  c-MYC-induced genomic instability. , 2014, Cold Spring Harbor perspectives in medicine.

[46]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[47]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[48]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[50]  Keda Yu,et al.  Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[51]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[52]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[53]  Michael Bittner,et al.  Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Pollack,et al.  Genomic instability in breast cancer: Pathogenesis and clinical implications , 2010, Molecular oncology.

[55]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Hortobagyi,et al.  Breast cancer metastasis: challenges and opportunities. , 2009, Cancer research.

[57]  B. Rasmussen,et al.  Prognostic effect of estrogen receptor status across age in primary breast cancer , 2007, International journal of cancer.

[58]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[59]  E. Paci,et al.  Female breast cancer. , 2004, Epidemiologia e prevenzione.